1. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial 
Anai E.S Durazzo, MD, Fábio S Machado, MD, Dimas T Ikeoka, MD, Cláudia De Bernoche, MD, Maristela C Monachini, MD, Pedro Puech-Leão, MD, Bruno Caramelli, MD 
Journal of Vascular Surgery 
Volume 39, Issue 5, Pages (May 2004)
DOI: /j.jvs

2. Fig 1 Flow diagram of trial phases.
Journal of Vascular Surgery  , DOI: ( /j.jvs )

3. Fig 2
Event-free survival in the 6 months after vascular surgery, according to study group. Outcome measures included death from cardiac causes, nonfatal acute myocardial infarction, ischemic stroke, and unstable angina. Rate of event-free survival at 6 months (180 days) was 91.4% in the atorvastatin group and 73.5% in the placebo group (P = .018).
Journal of Vascular Surgery  , DOI: ( /j.jvs )